Avanos Medical (AVNS) Cost of Revenue (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Cost of Revenue data on file, last reported at $88.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 13.26% year-over-year to $88.0 million; the trailing twelve-month figure through Mar 2026 stood at $357.6 million (up 14.29% YoY), and the FY2025 full-year result was $347.3 million, up 13.31% from the prior year.
• Cost of Revenue fell to $88.0 million in Q1 2026, from $94.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $94.9 million in Q4 2025 to a low of $67.9 million in Q1 2023.
• A 5-year average of $79.2 million and a median of $77.7 million in 2025 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 2148.57% in 2022, while the deepest fall reached 30.7% in 2022.
• Tracing AVNS's Cost of Revenue over 5 years: stood at $78.7 million in 2022, then dropped by 0.51% to $78.3 million in 2023, then climbed by 4.21% to $81.6 million in 2024, then advanced by 16.3% to $94.9 million in 2025, then retreated by 7.27% to $88.0 million in 2026.
• Business Quant data shows AVNS's Cost of Revenue at $88.0 million in Q1 2026, $94.9 million in Q4 2025, and $91.8 million in Q3 2025.